Policy
Jim O’Neill was deputy secretary at the Department of Health and Human Services and also acting director of the CDC after the abrupt ouster of Susan Monarez in August 2025.
FEATURED STORIES
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
Janssen Pharmaceutical, under parent organization Johnson & Johnson, secured an arbitrary win this week that results in royalty decisions stemming from licensing and marketing of daratumumab.
COVID-19 has killed more than six million people worldwide and almost one million in the U.S. And the pandemic isn’t over yet. Read on for that and more updates about COVID-19.
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
BMS partnered with digital oncology company GRYT Health to convene a series of “courageous conversations” between patients, practitioners, caregivers, clinical trial teams and public health leaders.
Stephane Bancel, the chief executive of Moderna, has likened the need for booster vaccine doses to the way Apple releases new smartphones every year.
The Accelerated Approval Integrity Act of 2022 (H.R. 6963) aims to remove loopholes in the FDA’s accelerated approval pathway. The bill, however, fails to adequately consider the whole picture.
The delay is related to a third-party secondary packaging and labeling facility that Alnylam planned to use for the launch of vutrisiran.
Norman E. “Ned” Sharpless will step down from his role as director of the National Cancer Institute (NCI) at the end of this month, after serving in the role since 2017.
David Sabatini’s resignation follows a decision from three senior MIT officers that recommended his tenure’s revocation.